Product Center
HRK-X Selected for Jiangsu Province's 2024 Innovative Pharmaceutical Equipment Special Award List!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08
- Views:
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
HRK-X Selected for Jiangsu Province's 2024 Innovative Pharmaceutical Equipment Special Award List!
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08 16:20
- Views:
Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.

As a preventive Category 1 biological product, HRK-X features a proprietary influenza virus subunit extraction process. This technology not only ensures the high purity of HA and NA proteins from all four vaccine strains and vaccine safety, but also demonstrates excellent immunogenicity. The product's quality standards exceed both Chinese Pharmacopoeia and EU Pharmacopoeia requirements, filling a domestic gap in this field!

Recently, at the Entrepreneurship Spirit Promotion Conference for Advancing New Industrialization, the Pharmaceutical High-Tech Zone (Gaogang District) awarded Mr. An Youcai, Chairman and General Manager of Ab&B Bio-Tech Co., Ltd., the honorary title of "Top Ten Star Entrepreneurs"! This recognition fully acknowledges Mr. An's and Ab&B Bio's pioneering spirit in developing and industrializing innovative human vaccines - their boldness to venture and innovate!

Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us